UNSPSC 51294510: Omiloxetine

This classification denotes an antidepressant agent with the molecular formula C27H25F2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, H8YI0SSF7B chemically known as 4'-fluoro-2-(trans-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidino)acetophenone but generally known as omiloxetine, which bears US NIH Compound Identifier 3047803. European Medicines Agency schedules Omiloxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09441MIG.

UNSPSC 51294510 Omiloxetine is a Commodity code that shows minimal recent state and local procurement activity aligned with its nominal scope. The three recent opportunities tagged under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are omiloxetine-specific, and the code's narrow product focus does not reflect the broader pharmaceutical sourcing and supply-chain work actually appearing in state and local solicitations today. The mismatch suggests either misclassification at the point of entry or that state and local procurement systems are using this code as a proxy for opioid-antagonist or general pharmaceutical commodity buys rather than as a true single-product UNSPSC line. State and local issuing bodies soliciting under this code span county health departments, state health agencies, and cooperative purchasing alliances managing multi-jurisdictional pharmaceutical distribution. Seminole County, Florida and the Texas Health and Human Services Commission appear as recent buyers, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration's Office of State Procurement managing a multi-state aggregated buy.

Recent activity concentrates in Florida and Texas, with multi-state reach through MMCAP's cooperative purchasing vehicle serving Minnesota and Oregon participants. The most concrete recent opportunity is Seminole County's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year initial term and one-year renewal option. The Texas HHS Commission issued an RFI (HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription programs for self-insured employee plans and state agencies, framed as preliminary market intelligence before a formal RFP. MMCAP posted an RFP (S1070000015802, posted January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across authorized wholesalers, with awards effective July 1, 2026, weighted 75 percent on price competitiveness and requiring cGMP and Drug Supply Chain Security Act certification. No omiloxetine-specific opportunities appear in the recent record.